An Open Label; Multicenter; Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor; MLN0128 (TAK-228); in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation